Moreover, HGT products are helping Shire meet its goal of global diversification, with REPLAGAL and ELAPRASE together now approved and in use in more than 40 countries, and 70% of HGT sales now generated outside the United States. Our world really is expanding rapidly at Shire, and we are taking aggressive steps to capitalize on-and to create-opportunities for patients around the world who do not yet have access to the life-altering medicines that we manufacture and sell.
Pressures abound in the current economy, but at Shire we're not just merely biding our time. We are moving forward-bolstering our pipeline through business-enhancing acquisitions, anticipating breakthroughs for patients with unmet needs, capitalizing on new patient populations, and looking for commonalities between our Specialty and HGT businesses. It's been an exciting time and the future promises even more. I thank my colleagues for continuing to help Shire live up to its own promise.
Shire's strategic goal is to become the leading specialty
biopharmaceutical company that focuses on meeting the needs of the specialist
physician. Shire focuses its business on ADHD, HGT and gastrointestinal
('GI') diseases as well as opportunities in other therapeutic areas to the
extent they arise through acquisitions. Shire's in-licensing, merger and
acquisition efforts are focused on products in specialist markets with strong
intellectual property protection and global rights. Shire believes that a
carefully selected and balanced portfolio of p
|SOURCE Shire Plc|
Copyright©2009 PR Newswire.
All rights reserved